Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab + octreotide + metronomic capecitabine in advanced well-differentiated neuroendocrine tumors
2006-004748-22Phase 2Active
- Sponsor
- San Luigi Gonzaga Hospital
- Start
- Jun 2007
- Modality
- Peptides, Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab, capecitabine and octreotide in apudoma (NET) and neuroendocrine carcinoma (NEC), sponsored by San Luigi Gonzaga Hospital. Primary endpoint: Objective response rate. Started Jun 2007; status: active.
02
Drugs
bevacizumabcapecitabineoctreotide
03
Conditions
apudoma (NET)neuroendocrine carcinoma (NEC)
Beyond the preview
Go deeper on 2006-004748-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-004748-22.